FDA bureaucrats are blocking life-saving rare disease treatments for 30 million Americans, betraying Trump administration promises of regulatory freedom and innovation.
Story Highlights
- FDA issued 23+ rejection letters since early 2025 for rare disease therapies, demanding impossible randomized trials despite tiny patient pools.
- Trump-appointed FDA Commissioner Marty Makary oversees shift to “gold standard science,” delaying gene therapies for Huntington’s, MPS II, and rare blood cancers.
- New “plausible mechanism” framework promises hope but contradicts ongoing rejections, eroding investor confidence and patient access.
- Patient advocates call it a “national disgrace,” urging Senate action to fulfill America First pledges against government overreach.
FDA Rejections Surge Amid Rare Disease Crisis
Since early 2025, the FDA has sent at least 23 complete response letters rejecting rare disease therapies. These include cell therapy for rare blood cancer by Atara Biotherapeutics and Pierre Fabre in January 2026, UniQure’s Huntington’s gene therapy on March 3, 2026, and programs from Replimune and Capricor. Regulators cite insufficient data from single-arm trials, unreliable biomarkers, and lack of placebos. Nearly 7,000 rare diseases afflict 30 million Americans, where patient pools under 200 worldwide make standard trials unfeasible. This rigidity prioritizes methodological purity over desperate patients facing months-long survival windows.
Trump Administration Pledges Clashes with FDA Actions
The Trump administration promised regulatory flexibility in 2025, with FDA leaders like Commissioner Marty Makary previewing a “plausible mechanism” approach in NEJM. Yet rejections persist, shifting from manufacturing issues to clinical doubts despite addressed fixes. Patient advocates like EveryLife Foundation’s Kennedy label 23+ refusals a betrayal of innovation pledges. Senate hearings criticize FDA handling, highlighting Orphan Drug Act incentives like tax credits and exclusivity now undermined by uncertainty. This erodes trust in government efficiency, a core conservative frustration with bureaucratic overreach.
New Framework Offers Limited Relief
On February 23, 2026, FDA and HHS released draft guidance for “plausible mechanism” approvals in ultra-rare cases like CRISPR and ASOs. It allows mechanism-of-action evidence plus confirmatory data, bypassing RCTs for n-of-1 treatments. Comments close April 27, 2026. FDA officials seek the “smallest spark” of effect, while Makary notes most approvals are rare disease drugs. Critics from Alliance for Regenerative Medicine decry a “toxic ideology” as rejections continue, signaling inconsistency like Moderna’s reversed flu vaccine refusal.
Patient and Industry Backlash Builds
Advocates like Adriana Herrera and Amy Comstock Rick testify on access delays for dying patients. Biotech firms face halted R&D, with analysts warning no certainty on approval paths. Leerink experts and UPenn clinicians argue traditional models fail individualized genetic therapies. Short-term, patients lose vital months; long-term, investment flees, widening gaps for 30 million untreated. This government blockade stifles American innovation, contradicting limited-government principles and fueling calls for accountability.
Short-term delays erode confidence, as companies like Pierre Fabre weigh regulatory risks. Economic fallout reduces Orphan Drug Act returns, deterring gene therapy advances. Social pressure mounts via Senate oversight, aligning with Trump pledges yet exposing federal failures. Broader signals of stricter standards threaten regenerative medicine progress, demanding conservative vigilance against eroding health freedoms.
Sources:
Axios: FDA’s Treatment of Rare Disease Patients Is a National Disgrace
C&EN: FDA plausible mechanism pathway for rare disease
FDA Insider: What’s Been Happening at the FDA Lately 2026
Rare Disease Advisor: Amy Comstock Rick on FDA Rare Disease Trial
RAPS: FDA’s Handling of Rare Disease Therapies Criticized
Ropes & Gray: Rare Disease in Focus at FDA – New Draft Guidance
